Last updated on August 2020

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Type 1 | Autoimmune disease | Diabetes (Pediatric) | Diabetes Mellitus Types I and II | Diabetes Mellitus | Diabetes Prevention | Insulin dependent diabetes mellitus
  • Age: Between 1 - 17 Years
  • Gender: Male or Female

Inclusion Criteria:

  • T1D for at least 6 months at the screening visit.
  • Have been treated with only one of the following rapid-acting insulin analogs as part of an multiple daily injection regimen for at least the last 90 days prior to the screening visit:
  • insulin lispro U-100, or
  • insulin aspart
  • insulin glulisine or
  • fast acting insulin aspart
  • Have been treated with only one of the following basal insulins for at least the last 90 days prior to the screening visit:
  • insulin glargine U-100 (once a day [QD] or twice a day [BID]), or
  • insulin detemir U-100 (QD or BID), or
  • insulin degludec U-100 (QD)
  • Have a HbA1c value 9.9% at the screening visit.

Exclusion Criteria:

  • Have current hypoglycemic unawareness or have had more than 1 episode of severe hypoglycemia within 6 months prior to the screening visit.
  • Have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months prior to the screening visit.
  • Have been on a treatment regimen that includes regular human insulin, neutral protamine Hagedorn (NPH), Afrezza (insulin human) inhalation powder, any premixed insulins or use of diluted insulins within 90 days prior to the screening visit.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.